Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05376891

Met Non Small Cell Cancer Registry (MOMENT)

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Klagenfurt Am Woerthersee, Klagenfurt, Austria

Loading trial locations.

About this study

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who signed ICF
  • Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
  • Participants who are starting or are already being treated with systemic therapy

Exclusion criteria

  • Participants who are enrolled in a clinical trial

Treatment and study plan

Primary outcomes

  1. Best Overall Response (BOR)

    Time frame: Through study completion, up to approximately 4.9 years

  2. Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

    Time frame: Up to approximately 4.9 years

  3. Overall Survival (OS)

    Time frame: Through study completion, up to approximately 4.9 years

  4. Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 4.9 years

  5. Number of Participants with Adverse Reactions (ARs)

    Time frame: Up to approximately 4.9 years

Study contacts

Contact information is provided by the study sponsor or research team.

Communication Center

CONTACT

[email protected]

+49 6151 72 5200

US Medical Information

CONTACT

[email protected]

888-275-7376

Sponsors and collaborators

Lead sponsor

EMD Serono Research & Development Institute, Inc.

Industry

Collaborators

  • Merck KGaA, Darmstadt, Germany

Registry information

Official study title

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
May 17, 2022
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.